Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 8/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.88 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27692935 | 1.00 | APOBEC3A (0.88) | APOBEC3AAPOBEC3GACHEALDH1A1KDM4E | |
| Bromide SCHEMBL80468 | 1.00 | APOBEC3A (0.88) | APOBEC3AAPOBEC3GACHEALDH1A1KDM4E | |
| Bromide SCHEMBL27702129 | 1.00 | APOBEC3A (0.88) | APOBEC3AAPOBEC3GACHEALDH1A1KDM4E | |
| Bromide SCHEMBL10995902 | 0.97 | APOBEC3A (0.82) | APOBEC3AAPOBEC3GACHEALDH1A1KDM4E | |
| Bromide SCHEMBL80467 | 0.97 | APOBEC3A (0.82) | APOBEC3AAPOBEC3GACHEALDH1A1KDM4E | |
| Bromide SCHEMBL3899564 | 0.97 | APOBEC3A (0.82) | APOBEC3AAPOBEC3GACHEALDH1A1KDM4E | |
| Bromide SCHEMBL27447054 | 0.97 | APOBEC3A (0.82) | APOBEC3AAPOBEC3GACHEALDH1A1KDM4E | |
| Bromide SCHEMBL30600378 | 0.97 | APOBEC3A (0.82) | APOBEC3AAPOBEC3GACHEALDH1A1KDM4E | |
| SCHEMBL12020269 | 0.97 | APOBEC3A (0.93) | APOBEC3AAPOBEC3GACHEALDH1A1KDM4E | |
| SCHEMBL147815 | 0.97 | APOBEC3A (0.93) | APOBEC3AAPOBEC3GACHEALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521733-B1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR | PFIZER PROD INC (US) | 2014-08-20 | — | — | EP | disclosed |
| CN-1989122-B | Novel cyclopenta [ b ] benzofuran derivatives and uses thereof | INTERMED DISCOVERY GMBH | 2013-07-24 | — | — | CN | disclosed |
| WO-2013068785-A1 | INDANONE AND INDANDIONE DERIVATIVES AND HETEROCYCLIC ANALOGS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-16 | — | — | WO | disclosed |
| US-7553877-B2 | Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma | PFIZER, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| CN-1989122-A | Novel cyclopenta [ b ] benzofuran derivatives and uses thereof | BAYER HEALTHCARE AG (DE) | 2007-06-27 | — | — | CN | disclosed |
| US-7138406-B2 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | PFIZER, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060247264-A1 | Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma | PFIZER INC | 2006-11-02 | — | — | US | disclosed |
| EP-1521733-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR | Pfizer Products Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| US-20040138262-A1 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | PFIZER INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004005229-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-5643904-A | Substituted hexahdryoazepinones and tetrahydrobenzazepinones | PFIZER INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5484917-A | FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL DISORDERS, PAIN AND ANXIETY | PFIZER INC. (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0625145-A1 | 3-PHENYLUREIDO-AZEPIN-2-ONES AND -BENZAZEPIN-2-ONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS | PFIZER INC. (US) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993015059-A1 | 3-PHENYLUREIDO-AZEPIN-2-ONES AND -BENZAZEPIN-2-ONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247264-A1 | Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma | NR3C1, NR3C2, LTB4R2 | ACHE 3701/4885APOBEC3A 4768/4885APOBEC3G 4837/4885 |
| US-20040138262-A1 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | NR3C1, MC2R, FPR1 | ACHE 3783/4885APOBEC3A 4878/4885APOBEC3G 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.